Shares of Oncolytics Biotech, Inc. (NASDAQ:ONCY) were up 16.7% on Friday . The stock traded as high as $0.74 and last traded at $0.63, approximately 1,263,755 shares changed hands during mid-day trading. An increase of 1,013% from the average daily volume of 113,517 shares. The stock had previously closed at $0.54.
Several analysts recently weighed in on ONCY shares. ValuEngine upgraded Oncolytics Biotech from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research downgraded Oncolytics Biotech from a “buy” rating to a “hold” rating in a report on Tuesday, July 9th.
The company has a quick ratio of 3.39, a current ratio of 3.21 and a debt-to-equity ratio of 0.08. The firm has a fifty day moving average of $1.40 and a two-hundred day moving average of $1.77.
A hedge fund recently bought a new stake in Oncolytics Biotech stock. Verition Fund Management LLC acquired a new stake in Oncolytics Biotech, Inc. (NASDAQ:ONCY) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 408,838 shares of the company’s stock, valued at approximately $695,000. Verition Fund Management LLC owned approximately 2.01% of Oncolytics Biotech at the end of the most recent reporting period. Institutional investors and hedge funds own 1.02% of the company’s stock.
About Oncolytics Biotech (NASDAQ:ONCY)
Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.
Featured Story: What is an investor looking for in an SEC filing?
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.